Abbott (ABT) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY25 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Abbott Labs (ABT) PT Lowered to $155 at Citi
July 18, 2025 10:03 AM EDTCiti analyst Joanna Wuensch lowered the price target on Abbott Labs (NYSE: ABT) to $155.00 (from $157.00) while maintaining a Buy rating.
The analyst comments "This was a somewhat precarious setup for ABT heading into the quarter, priced for a beat-and-raise, which did not... More
Goldman Sachs Reiterates Buy Rating on Abbott Labs (ABT)
July 17, 2025 9:45 AM EDTGoldman Sachs analyst David Roman reiterated a Buy rating and $153.00 price target on Abbott Labs (NYSE: ABT).
The analyst comments "This morning, Abbott reported 2Q25 results and updated 2025 guidance. The headline that we expect to gain most attention is the reduction to the... More
